Search alternatives:
less decrease » teer decrease (Expand Search), we decrease (Expand Search), levels decreased (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
less decrease » teer decrease (Expand Search), we decrease (Expand Search), levels decreased (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
9801
-
9802
-
9803
-
9804
Primers for qPCR.
Published 2025“…Results revealed the MRE11–RAD50–NBS1 (MRN) complex as a potential factor. Transiently or stably knockdown of MRE11, RAD50 or NBS1 in hepatocytes before HBV infection significantly decreased viral markers, including cccDNA, while reconstitution reversed the effect. …”
-
9805
Antibodies used for western blotting.
Published 2025“…Results revealed the MRE11–RAD50–NBS1 (MRN) complex as a potential factor. Transiently or stably knockdown of MRE11, RAD50 or NBS1 in hepatocytes before HBV infection significantly decreased viral markers, including cccDNA, while reconstitution reversed the effect. …”
-
9806
Target sequences of siRNAs.
Published 2025“…Results revealed the MRE11–RAD50–NBS1 (MRN) complex as a potential factor. Transiently or stably knockdown of MRE11, RAD50 or NBS1 in hepatocytes before HBV infection significantly decreased viral markers, including cccDNA, while reconstitution reversed the effect. …”
-
9807
Plasmids information.
Published 2025“…Results revealed the MRE11–RAD50–NBS1 (MRN) complex as a potential factor. Transiently or stably knockdown of MRE11, RAD50 or NBS1 in hepatocytes before HBV infection significantly decreased viral markers, including cccDNA, while reconstitution reversed the effect. …”
-
9808
Raw data.
Published 2025“…Results revealed the MRE11–RAD50–NBS1 (MRN) complex as a potential factor. Transiently or stably knockdown of MRE11, RAD50 or NBS1 in hepatocytes before HBV infection significantly decreased viral markers, including cccDNA, while reconstitution reversed the effect. …”
-
9809
Table 1_The association between oxidative balance scores and all-cause mortality and cancer-specific mortality in cancer survivors: a retrospective cohort study.doc
Published 2025“…A similar significant association was found with cancer-specific mortality, while no significant association was noted for CVD mortality. …”
-
9810
Clinical and epidemiological data of patients.
Published 2025“…CTG showed a significant reduction in pain within 24 hours in the per-protocol analysis (Log-rank <i><i>p</i></i> = <i><i>0.04</i></i>). …”
-
9811
Supplementary Material for: SPECKLE TRACKING ECHOCARDIOGRAPHY IN TWIN PREGNANCIES AND THE ROLE OF GLOBAL LONGITUDINAL STRAIN AND PEAK SYSTOLIC STRAIN: A SYSTEMATIC REVIEW AND META-...
Published 2024“…The global longitudinal strain in the right and left ventricle and the peak systolic strain in the right ventricle of the recipient MCDA twin is significantly decreased compared to the donor MCDA twin. 2D STE assessment was shown feasible and reproducible in MCDA pregnancies. …”
-
9812
Image1_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF
Published 2024“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
-
9813
Image2_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF
Published 2024“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
-
9814
Image8_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF
Published 2024“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
-
9815
Image5_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF
Published 2024“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
-
9816
Image6_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF
Published 2024“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
-
9817
Image3_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF
Published 2024“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
-
9818
Image4_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF
Published 2024“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
-
9819
Image7_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF
Published 2024“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
-
9820
WHODAS Outcomes (ITT Analysis).
Published 2025“…CTG showed a significant reduction in pain within 24 hours in the per-protocol analysis (Log-rank <i><i>p</i></i> = <i><i>0.04</i></i>). …”